Summary
Background: The number of effective cytotoxic agents for the treatment of patients with metastatic adult type soft tissue sarcoma (STS) is limited, when patients have failed anthracyline-based chemotherapy. The aim of this trial was to evaluate the efficacy of gemcitabine in this setting. Methods: Between August 2001 and March 2003 19 patients were eligible to enter. Gemcitabine was administered as a 30-minutes infusion at a dosage of 1 g/m2 on day 1, 8 and 15 every 4 weeks. All patients had progressive disease during (n = 12) or shortly after an anthracycline-based regimen (n = 3). Results: Four of 19 patients did not start study treatment because of fulminant progression. Fifteen patients with a median age 47 years (32–72) were assessable. All patients had received at least one prior treatment regimen (range, 1–6) for metastatic disease containing anthracyclines (n = 15) and ifosfamide (n = 11). To date, a total of 72+ cycles have been applied (median; 3, 1–28+). Seven patients (47%) had progressive disease after completion of two cycles at the first response assessment. One patient (6%) attained a partial remission, and 7 patients (47%) achieved disease stabilisations. One patient is still on treatment after more than 2.5 years. The calculated progression-free rate at 3 and 6 months was 46.7% (CI95%, 21.4–71.9) and 13.3% (CI95%, (0–30.5). 95% of the cycles have been applied without any dose modification or treatment delay. Conclusions: Considering response and progression-free rate as the primary endpoints for phase II trials in pretreated STS, gemcitabine has moderate efficacy.
Similar content being viewed by others
References
Patel SR: Systemic chemotherapy, in Pollock RE (ed): Soft tissue sarcomas, Hamilton Ontario, Canada, 2002, pp 323–328
Hartmann JT, Patel S: Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 65: 167–178, 2005
Benjamin RS, Legha SS, Patel SR, Nicaise C: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 31(Suppl 2): S174–S179, 1993
Borden EC, Amato DA, Rosenbaum C, Enterline HT, Shiraki MJ, Creech RH, Lerner HJ, Carbone PP: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5: 840–850, 1987
Lopez M, Vici P, Di Lauro L, Carpano S: Increasing single epirubicin doses in advanced soft tissue sarcomas. J Clin Oncol 20: 1329–1334, 2002
Lorigan PC, Verweij J, Papai Z, Rodenhuis S, le Cesne A, Leahy MG, Radford J, Hogendoorn PC, Van Glabbeke M, Kirkpatrick A, Nielsen OS: Randomised phase III trial of two investigational schedules of ifosfamide versus standard dose doxorubicin in patients with advanced or metastatic soft tissue sarcoma (ASTS). Proc Am Soc Clin Oncol 21: 2002 (abstr. 1616)
Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, Steward W, Daugaard S, VanGlabbeke M, Kirkpatrick A, Tursz T: High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer 78: 1634–1639, 1998
Cure H, Krakowski I, Adenis A, Tubiana N, Kerbrat P, Roche H, Chevallier B, Lentz MA, Fumoleau P, Chollet P: Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group. Eur J Cancer 34: 422–423, 1998
Hartmann JT, Oechsle K, Mayer F, Kanz L, Bokemeyer C: Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res 23(2C): 1899–1901, 2003
Reichardt P, Oechsle K, Pink D, Bokemeyer C, Schneller F, Issels R, Kanz L, Hartmann JT: An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 21: 481–486, 2003
Balcerzak SP, Benedetti J, Weiss GR, Natale RB: A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 76: 2248–2252, 1995
Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients—preliminary evidence of activity. J Clin Oncol 19: 1248–1255, 2001
Look KY, Sandler A, Blessing JA, Lucci JA III, Rose PG: Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92: 644–647, 2004
Merimsky O, Meller I, Flusser G, Kollender Y, Issakov J, Weil-Ben-Arush M, Fenig E, Neuman G, Sapir D, Ariad S, Inbar M: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45: 177–181, 2000
Merimsky O, Meller I, Kollender Y, Inbar M: Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy. Eur J Cancer 34: 1296–1297, 1998
Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E: Phase II trial of gemcitabine in advanced sarcomas. Cancer 94: 3225–3229, 2002
Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH: Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97: 1969–1973, 2003
Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS: Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 19: 3483–3489, 2001
Spath-Schwalbe E, Genvresse I, Koschuth A, Dietzmann A, Grunewald R, Possinger K: Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs 11: 325–329, 2000
Svancarova L, Blay JY, Judson IR, van Hoesel QG, van Oosterom AT, le Cesne A, Keizer HJ, Hermans C, Van Glabbeke M, Verweij J, Hogendoorn PC, Nielsen OS: Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38: 556–559, 2002
WHO: International classification of diseases, 10th edition (ICD-10), in WHO (ed): Geneva, 1996
Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143–151, 1982
Kaplan EL, Maier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Burton GV, Rankin C, Flaherty LE, Borden EC, Mills GM, Antman KH: Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcomas (STS). Proc Am Soc Clin Oncol 22: 820, 2003 (abstr. 3297)
Lopez-Pousa A, Buesa J, Casado A, Garcia del Muro J, Poveda A, Maurel J, Martin J, Balana C, Martinez J: Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS). J Clin Oncol 22: 14S, 2004 (abstr. 9033)
Buesa JM, Losa R, Fernandez A, Sierra M, Esteban E, Diaz A, Lopez-Pousa A, Fra J: Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer 101: 2261–2269, 2004
Morgan JA, George S, Desai J, Amand MS, Horton D, Wilkins E, Manola J, Demetri GD: Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS). J Clin Oncol 22: 14S, 2004 (abstr. 9009)
Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20: 2824–2831, 2002
Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Lee JS, Couwlier C, Palazzolo K, Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 22: 1706–1712, 2004
Pisters PW, Ballo MT, Bekele N, Thall PF, Feig BW, Lin P, Cormier JN, Benjamin RS, Patel SR: Phase I trial using toxicity severity weights for dose finding of gemcitabine combined with radiation therapy and subsequent surgery for patients with extremity and trunk soft tissue sarcomas. J Clin Oncol 22: 14S, 2004 (abstr. 9008)
Van Glabbeke M, Verweij J, Judson I, Nielsen OS: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38: 543–549, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hartmann, J.T., Oechsle, K., Huober, J. et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs 24, 249–253 (2006). https://doi.org/10.1007/s10637-005-3537-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-005-3537-1